AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Agreement Entered For Manufacturing Monoclonal Antibodies On Human Cell Line.(Brief Article)
2002 FEB 20 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell (CRXL) and Belgian biotechnology company Innogenetics (INNX) have entered into a nonexclusive license agreement for the manufacturing of monoclonal antibody products on Crucell's human cell line PER.C6.
Under the terms of the agreement, Innogenetics will use the PER.C6 platform to develop monoclonal antibodies in the context of its therapeutic programs, and will be able to manufacture and market the emerging therapeutic products.
Crucell's CEO Dinko Valerio welcomes Innogenetics as its launching customer for antibody production. "We are delighted with Innogenetics' choice for our technology in the context of its therapeutic programs. After the successful commercialization of PER.C6 for vaccines and gene therapy, this deal is a vital step towards rolling ...
- Functional Genetics Inc and ProBioGen AG close antibody production agreement.
- News wire article from: Chemical Business Newsbase November 12, 2008 700+ words
...announced the successful completion of a cell line development contract and the start of an antibody production agreement. Functional Genetics' pipeline...successfully developed a new production cell line for the TSG101 programme which matched...
- Morphotek and SC BioSciences Announce a Business Collaboration for the...
- Press release article from: PR Newswire November 15, 2004 700+ words
...partner for Morphotek's cell line optimization services...which rapidly evolves antibody production cell lines to generate subclones...overcome the bottlenecks in cell-line development and antibody production. We are pleased to be Morphotek...
- Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of...
- Press release article from: PR Newswire September 3, 2008 700+ words
...milestone in CHO based monoclonal antibody production with the achievement of manufacturing...stable Selexis CHO production cell line rapidly generated by industry...development of a high-performance cell line development at Selexis...with a high-performance cell line, ...
- Antibody production cartridge.(Editor's Choice)
- Magazine article from: Bioscience Technology May 1, 2009 700+ words
...cartridge from FiberCell Systems is optimized for maximum antibody production when used with the new FiberCell Systems Duet pump. This...produce from 10 mgs to 100 rags of antibody from a hybridoma cell line every two days in a total volume of 20 mls for as long as...
- Press Release: Crucell and Applied Molecular Evolution sign PER C6 antibody...
- News wire article from: Asia Africa Intelligence Wire October 1, 2002 700+ words
...monoclonal antibodies on the PER C6 human cell line. Applied Molecular Evolution also has...monoclonal antibody products on the PER C6 cell line. Additionally, Crucell has granted...Molecular Evolution programmes on the PER C6 cell line. Under the terms of the agreement...
- DSM Biologics and Crucell Announce PER.C6 Licensing Agreement with Biotecnol SA...
- News wire article from: Europe Intelligence Wire January 5, 2007 700+ words
...allows Biotecnol to use the PER.C6 human cell line for preclinical and phase 1 clinical...In our opinion, the PER.C6 human cell line is now an established technology. We...its proprietary expression technology, cell line development capabilities, upstream and...
- Cell Genesys reports potential breakthrough in antibody production technology.
- Newspaper article from: BIOTECH Patent News April 1, 2005 700+ words
...that enables the production of full-length monoclonal antibodies at commercially relevant levels from a single production cell line. Moreover, the time required to develop cell lines that can be used for commercial production can be significantly shortened...
- Cell Genesys Reports Potential Breakthrough in Antibody Production Technology;...
- Press release article from: PR Newswire April 19, 2005 700+ words
...that enables the production of full-length monoclonal antibodies at commercially relevant levels from a single production cell line. Moreover, the time required to develop cell lines that can be used for commercial production can be significantly shortened...
- Crucell and DSM Announce PER.C6[R] Licensing Agreement with MorphoSys for...
- News wire article from: Europe Intelligence Wire September 8, 2004 700+ words
...Prime Standard Segment). Under the terms of the agreement, MorphoSys receives rights to Crucell's PER.C6[R] human cell line technology for use in its antibody research programs as well as an option to a license for the clinical and commercial production...
- Crucell and DSM Announce PER.C6[R] Licensing Agreement with PanGenetics for...
- News wire article from: Europe Intelligence Wire June 8, 2004 700+ words
...R] research license agreement with PanGenetics B.V. This license agreement allows PanGenetics to use the PER.C6[R] cell line for preclinical manufacturing of certain recombinant monoclonal antibody products. Under the terms of the agreement, Crucell...
Source: HighBeam Research, Agreement Entered For Manufacturing Monoclonal Antibodies On Human...